Ask AI
ProCE Banner Activity

Managing CMV Risk in HCT Recipients: Optimizing Transplant Outcomes Through Contemporary CMV Management

Podcast Episodes

Cytomegalovirus (CMV) infection is one of the most significant infectious complications after hematopoietic cell transplant (HCT). In this podcast, featuring curated audio from a live satellite symposium, experts Roy F. Chemaly, MD, MPH, FIDSA, FACP, FESCMID, and Marcus Pereira, MD, MPH, FAST, discuss the burden of CMV in HCT recipients and explore strategies to effectively identify and monitor high-risk patients.

Released: March 09, 2026

Review Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Takeda Pharmaceuticals U.S.A., Inc.

Target Audience

This activity is intended for clinical specialists, including physicians, clinical pharmacists, advanced practice providers, and other healthcare professionals who care for HCT recipients with CMV infections. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe the comprehensive burden of CMV replication on post-HCT clinical courses

  • Update strategies for timely identification of HCT recipients with, or at risk for, CMV infections with inadequate response to initial therapies

Faculty Disclosure

Primary Author

Roy F. Chemaly, MD, MPH, FIDSA, FACP, FESCMID: consultant/advisor/speaker: ADMA Biologics, AiCuris, Astellas, Biotest, Gilead, Invivyd, Merck/MSD, Moderna, Pfizer, Shionogi, Symbio, Takeda; researcher: AiCuris, Ansun, Eurofins-Viracor, Genentech, Karius, Merck, OM1, Symbio, Takeda.

Marcus Pereira, MD, MPH, FAST, has no relevant financial relationships to disclose.